

**PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE
COVERAGE INFORMATION AND SPECIAL CONSIDERATIONS**

Florida Medicaid providers administering vaccines to Florida Medicaid recipients, must submit two Current Procedural Terminology (CPT) codes: a vaccine product code as well as the vaccine administration code on the claim for reimbursement of administration from Florida Medicaid for recipients enrolled in the fee-for-service delivery system. A corresponding administration code must be submitted for each vaccine administered during the same visit on the claim form.

Florida Medicaid providers receiving vaccine products through the Vaccine for Children (VFC) Program for fee-for-service recipients 0 through 18 years of age are reimbursed for the administration of the vaccine(s) only. The vaccine product codes are reimbursed at \$0.00, vaccine administration codes are reimbursed in accordance with rates established on this fee schedule.

MediKids enrolls children one through four years of age and are eligible for all immunizations recommended by the Advisory Committee on Immunization Practices (ACIP) for this age group. Florida Medicaid providers who administer vaccines to MediKids enrollees are to be reimbursed for the vaccine products and administration services by the Managed Care Plan. MediKids enrollees are not eligible to receive products provided through the VFC Program.

Administration services are reimbursed at 80% of the maximum fee when performed by an advanced practice registered nurse (APRN), physician's assistant (PA), or registered pharmacist (RPh).

Florida Medicaid providers administering COVID-19 vaccines to Florida Medicaid recipients must submit both the appropriate CPT code for the specific vaccine product in conjunction with the product specific vaccine administration code on the claim for reimbursement of administration from Florida Medicaid for recipients enrolled in the fee-for-service delivery system. The manufacturer-specific products and their dose-specific administration code must be submitted for each vaccine dose administered on the claim form.

**COVID-19 Vaccine & Administration Codes as of September 12, 2023.*

Italicized print, not authorized for use in the United States as of September 11, 2023.

^Respiratory Syncytial Virus monoclonal antibody codes have specific administration codes that must be billed together.

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: OCTOBER 1, 2023

| Code | Modifier | Description | Units | Age (Years) | MaxFee |
|-------|----------|---|-------|-------------|--------|
| 90688 | | Influenza vaccine intramuscular administration, 0.5ml dosage, quadrivalent MDV | 1 | 0 - 18 | 0.00 |
| 90688 | HA | Influenza vaccine intramuscular administration, 0.5ml dosage, quadrivalent MDV | 1 | 19+ | 18.44 |
| 90685 | | Influenza vaccine, intramuscular administration, 0.25ml dosage, quadrivalent, preservation free | 1 | 0-3 | 0.00 |
| 90686 | | Influenza vaccine, intramuscular administration, 0.5ml dosage, quadrivalent, preservation free | 1 | 0 - 18 | 0.00 |
| 90686 | HA | Influenza vaccine, intramuscular administration, 0.5ml dosage, quadrivalent, preservation free | 1 | 19+ | 19.73 |
| 90657 | | Influenza vaccine for administration into muscle, 0.25ml dosage | 1 | 0-2 | 0.00 |
| 90658 | | Influenza vaccine for administration into muscle, 0.5ml dosage | 1 | 0 - 18 | 0.00 |
| 90658 | HA | Influenza vaccine for administration into muscle, 0.5ml dosage | 1 | 19+ | 19.22 |
| 90620 | | Meningococcus recombinant protein for injection into muscle, 2 dose schedule (MenB-4C) | 1 | 10-18 | 0.00 |
| 90620 | HA | Meningococcus recombinant protein for injection into muscle, 2 dose schedule (MenB-4C) | 1 | 19+ | 211.32 |
| 90715 | | Tetanus, diphtheria toxoids, and acellular pertussis (whooping cough) (Tdap), intramuscular | 1 | 7 - 18 | 0.00 |

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: OCTOBER 1, 2023

| Code | Modifier | Description | Units | Age (Years) | MaxFee |
|-------------|-----------------|--|--------------|--------------------|---------------|
| 90715 | HA | Tetanus, diphtheria toxoids, and acellular pertussis (whooping cough) (TDaP), intramuscular | 1 | 19+ | 52.41 |
| 90700 | | Diphtheria, tetanus, and acellular pertussis (whooping cough) (DTaP), intramuscular | 1 | 0-6 | 0.00 |
| 90702 | | Diphtheria and tetanus toxoids, intramuscular | 1 | 0-7 | 0.00 |
| 90682 | | Influenza vaccine derived from DNA (RIV4) for injection into muscle, quadrivalent, preservative and antibiotic free (Flublok) | 1 | 18 | 0.00 |
| 90682 | HA | Influenza vaccine derived from DNA (RIV4) for injection into muscle, quadrivalent, preservative and antibiotic free (Flublok) | 1 | 19+ | 63.76 |
| 90756 | | Influenza vaccine derived from cell cultures, intramuscular, quadrivalent, antibiotic free, 0.5ml | 1 | 0-18 | 0.00 |
| 90674 | | Influenza vaccine derived from cell cultures (ccIV4) preservative/antibiotic free 0.5ml intramuscular | 1 | 0-18 | 0.00 |
| 90674 | HA | Influenza vaccine derived from cell cultures (ccIV4) preservative/antibiotic free 0.5ml intramuscular | 1 | 19+ | 30.10 |
| 90756 | HA | Influenza vaccine derived from cell cultures, intramuscular, quadrivalent, antibiotic free, 0.5ml | 1 | 19+ | 28.52 |
| 90687 | | Influenza vaccine intramuscular administration, 0.25ml dosage, quadrivalent | 1 | 0-3 | 0.00 |
| 90672 | | Influenza vaccine quadrivalent, nasal administration | 1 | 2-18 | 0.00 |
| 90672 | HA | Influenza vaccine quadrivalent, nasal administration | 1 | 19+ | 23.75 |
| 90655 | | Influenza vaccine for administration into muscle, 0.25ml dosage, preservative free | 1 | 0-2 | 0.00 |
| 90656 | | Influenza vaccine for administration into muscle, 0.5ml dosage, preservative free | 1 | 0 - 18 | 0.00 |
| 90656 | HA | Influenza vaccine for administration into muscle, 0.5ml dosage, preservative free | 1 | 19+ | 19.76 |
| 90651 | | Human papilloma virus nonvalent (3 dose schedule) injection into muscle | 1 | 9 - 18 | 0.00 |
| 90651 | HA | Human papilloma virus nonvalent (3 dose schedule) injection into muscle | 1 | 19-45 | 268.77 |
| 90739 | | Hepatitis B adult dosage (2 dose schedule) injection into muscle | 1 | 18 | 0.00 |
| 90739 | HA | Hepatitis B adult dosage (2 dose schedule) injection into muscle | 1 | 19+ | 140.60 |
| 90648 | | Haemophilus influenzae B (4 dose schedule) injection into muscle | 1 | 0-5 | 0.00 |
| 90375 | | Rabies immune globulin for injection beneath skin and/or into muscle | 9 | | 284.68 |
| 90376 | | Rabies immune globulin for injection beneath skin and/or into muscle, heat treated | 9 | | 250.09 |
| 90675 | | Rabies vaccine, intramuscular | 1 | | 329.99 |
| 90713 | | Polio vaccine, injection beneath the skin or into muscle | 1 | 0-18 | 0.00 |
| 90734 | | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or (MenACWY-CRM) for injection into muscle | 1 | 0-18 | 0.00 |

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: OCTOBER 1, 2023

| Code | Modifier | Description | Units | Age (Years) | MaxFee |
|-------|----------|--|-------|-------------|--------|
| 90734 | HA | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or (MenACWY-CRM) for injection into muscle | 1 | 19+ | 148.49 |
| 90644 | | Meningococcal and Haemophilus influenzae B (4 dose schedule) injection into muscle, children 6 weeks-18 months of age (Hib-MenCY) | 1 | 0-2 | 0.00 |
| 90619 | | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT) for injection into muscle | 1 | 2-18 | 0.00 |
| 90619 | HA | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT) for injection into muscle | 1 | 19+ | 156.11 |
| 90707 | | Measles, mumps, and rubella (German measles) injection beneath skin | 1 | 0-18 | 0.00 |
| 90707 | HA | Measles, mumps, and rubella (German measles) injection beneath skin | 1 | 19+ | 89.87 |
| 90723 | | Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), Hepatitis B, and polio (DTaP-HepB-IPV), intramuscular | 1 | 0-6 | 0.00 |
| 90647 | | Haemophilus influenzae B (3 dose schedule) injection into muscle | 1 | 0-5 | 0.00 |
| 90698 | | Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), Haemophilus influenza type B and polio (DTaP-HIB-IPV), intramuscular | 1 | 0-4 | 0.00 |
| 90732 | | Pneumococcal polysaccharide 23 valent subcutaneous or intramuscular | 1 | 2 - 18 | 0.00 |
| 90732 | HA | Pneumococcal polysaccharide 23 valent subcutaneous or intramuscular | 1 | 19+ | 117.08 |
| 90670 | | Pneumococcal conjugate 13 valent, intramuscular | 1 | 0-18 | 0.00 |
| 90671 | | Pneumococcal Conjugate Vaccine 15 valent, intramuscular (PCV15) | 1 | 0-18 | 0.00 |
| 90671 | HA | Pneumococcal Conjugate Vaccine 15 valent, intramuscular (PCV15) | 1 | 19+ | 215.37 |
| 90677 | | Pneumococcal Conjugate Vaccine 20 valent, intramuscular (PCV20) | 1 | 0-18 | 0.00 |
| 90677 | HA | Pneumococcal Conjugate Vaccine 20 valent, intramuscular (PCV20) | 1 | 19+ | 253.21 |
| 90710 | | Measles, mumps, rubella (German measles), and varicella (chicken pox) injection beneath skin | 1 | 1 - 12 | 0.00 |
| 90696 | | Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), and polio (DTaP-IPV), intramuscular | 1 | 4 - 6 | 0.00 |
| 90743 | | Hepatitis B 2 (dose schedule) intramuscular | 1 | 11 - 15 | 0.00 |
| 90744 | | Hepatitis B (3 dose schedule) intramuscular | 1 | 0-18 | 0.00 |
| 90746 | | Hepatitis B (3 dose schedule) intramuscular | 1 | 19+ | 64.90 |
| 90681 | | Rotavirus pentavalent (2 dose schedule) oral | 1 | 0-1 | 0.00 |
| 90680 | | Rotavirus pentavalent (3 dose schedule) oral | 1 | 0-1 | 0.00 |
| 90714 | | Tetanus and diphtheria toxoids, intramuscular | 1 | 7 - 18 | 0.00 |
| 90714 | HA | Tetanus and diphtheria toxoids, intramuscular | 1 | 19+ | 39.74 |

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: OCTOBER 1, 2023

| Code | Modifier | Description | Units | Age (Years) | MaxFee |
|-------|----------|---|-------|---------------------------|--------|
| 90621 | | Meningococcus lipoprotein for injection into muscle, 2 or 3 dose schedule (MenB-FHbp) | 1 | 10-18 | 0.00 |
| 90621 | HA | Meningococcus lipoprotein for injection into muscle, 2 or 3 dose schedule (MenB-FHbp) | 1 | 19+ | 178.95 |
| 90632 | | Hepatitis A injection into muscle, adult dosage | 1 | 18 | 0.00 |
| 90632 | HA | Hepatitis A injection into muscle, adult dosage | 1 | 19+ | 76.69 |
| 90633 | | Hepatitis A (2 dose schedule) injection into muscle, pediatric or adolescent dosage | 1 | 0-18 | 0.00 |
| 90634 | | Hepatitis A (3 dose schedule) injection into muscle, pediatric or adolescent dosage | 1 | 0-18 | 0.00 |
| 90716 | | Varicella virus (chicken pox) subcutaneous | 1 | 0-18 | 0.00 |
| 90716 | HA | Varicella virus (chicken pox) subcutaneous | 1 | 19+ | 160.36 |
| 90697 | | Diphtheria, tetanus toxoids, acellular pertussis (whooping cough), polio, Haemophilus influenza type b and hepatitis B (DTaP-IPV-HIB-HEPB), intramuscular | 1 | 0-4 | 0.00 |
| 90678 | | Respiratory Syncytial Virus vaccine, Bivalent, 0.5ml for IM use (ABRYSVO) | 1 | 10-18 (PREGNANCY ONLY) | 295.00 |
| 90678 | HA | Respiratory Syncytial Virus vaccine, Bivalent, 0.5ml for IM use (ABRYSVO) | 1 | 19-59 (PREGNANCY ONLY) | 295.00 |
| 90678 | HA | Respiratory Syncytial Virus vaccine, Bivalent, 0.5ml for IM use (ABRYSVO) | 1 | 60+ | 295.00 |
| 90679 | | Respiratory Syncytial Virus vaccine, for IM use (AREXVY) | 1 | 60+ | 280.00 |
| 90380 | | <i>Respiratory Syncytial Virus monoclonal antibody, seasonal dose; 0.5ml dosage for IM use (BEYFORTUS)^</i> | 1 | 0-1 | 0.00 |
| 90381 | | <i>Respiratory Syncytial Virus monoclonal antibody, seasonal dose; 1ml dosage for IM use (BEYFORTUS)^</i> | 1 | 0-1 | 0.00 |
| 90381 | | <i>Respiratory Syncytial Virus monoclonal antibody, seasonal dose; 1ml dosage for IM use (BEYFORTUS)^</i> | 2 | 1-2 | 0.00 |
| 96380 | | <i>Administration of Respiratory Syncytial Virus monoclonal antibody, seasonal dose, intramuscular, with counseling^</i> | 1 | 0-2 | 10.00 |
| 96381 | | <i>Administration of Respiratory Syncytial Virus monoclonal antibody, seasonal dose, intramuscular^</i> | 1 | 0-2 | 10.00 |
| 90750 | | Zoster Vaccine (HZC) recombinant, intramuscular | 1 | 18+ | 183.41 |

ADMINISTRATION CODES

| | | | | | |
|-------|--|---|--|------|-------|
| 90460 | | Administration of first vaccine or toxoid component through 18 years of age, with counseling | | 0-18 | 10.00 |
| 90471 | | Administration of one vaccine, single or combination vaccine/toxoid. (percutaneous, intradermal, subcutaneous or intramuscular) | | | 10.00 |
| 90472 | | Administration of each additional vaccine, single or combination vaccine/toxoid. (percutaneous, intradermal, subcutaneous or intramuscular) | | | 10.00 |
| 90473 | | Immunization administration by intranasal or oral route of one vaccine, single or combination vaccine/toxoid. | | | 10.00 |
| 90474 | | Administration of each additional intranasal or oral vaccine (single or combination vaccine/toxoid) | | | 10.00 |

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: OCTOBER 1, 2023

| Code | Modifier | Description | Units | Age (Years) | MaxFee |
|--|----------|---|-------|-------------|--------|
| COVID-19 VACCINE & ADMINISTRATION CODES | | | | | |
| 90480 | | Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose (all manufacturers)* | 1 | ANY | 40.00 |
| 91318 | | Severe acute respiratory coronavirus 2 (SARS-CoV-2-) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 0.3 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use (Pfizer)* | 1 | 6MO-4YRS | 0.00 |
| 91319 | | Severe acute respiratory coronavirus 2 (SARS-CoV-2-) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 0.3 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use (Pfizer)* | 1 | 5-11YRS | 0.00 |
| 91320 | | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 0.3 mL dosage, tris-sucrose formulation, for intramuscular use (Pfizer)* | 1 | 12-18 | 0.00 |
| 91320 | HA | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, 0.3 mL dosage, tris-sucrose formulation, for intramuscular use (Pfizer)* | 1 | 19+ | 115.00 |
| 91321 | | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 0.25 mL dosage, for intramuscular use (Moderna)* | 1 | 6MO-11YRS | 0.00 |
| 91322 | | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 0.5 mL dosage, for intramuscular use (Moderna)* | 1 | 12-18 | 0.00 |
| 91322 | HA | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 0.5 mL dosage, for intramuscular use (Moderna)* | 1 | 19+ | 128.00 |
| 91304 | | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 0.5mL dosage, for intramuscular use (Novavax) | 1 | 12+ | 0.00 |
| 91312 | PFIZER | SARSCOV2 VAC BVL 30MCG/0.3ML (GRAY CAP) | 1 | 12+ | 0.00 |
| 0121A | PFIZER | ADM SARSCV2 BVL 30MCG/.3ML SINGLE DOSE (GRAY CAP) | 1 | 12+ | 0.00 |
| 0124A | PFIZER | ADM SARSCV2 BVL 30MCG/.3ML BOOSTER (GRAY CAP) | 1 | 12+ | 40.00 |
| 91315 | PFIZER | SARSCOV2 VAC BVL 10MCG/0.2ML (ORANGE CAP) | 1 | 5-11 | 0.00 |
| 0151A | PFIZER | ADM SARSCOV2 BVL 10MCG/0.2ML SINGLE DOSE (ORANGE CAP) | 1 | 5-11 | 40.00 |
| 0154A | PFIZER | ADM SARSCOV2 BVL 10MCG/0.2ML (ORANGE CAP) | 1 | 5-11 | 40.00 |
| 91317 | PFIZER | SARSCOV2 VAC BVL 3MCG/0.2ML (MAROON CAP) | 1 | 6MO- 4YRS | 0.00 |
| 0171A | PFIZER | ADM SARSCV2 BVL 3MCG/0.2ML FIRST DOSE (MAROON CAP) | 1 | 6MO- 4YRS | 40.00 |
| 0172A | PFIZER | ADM SARSCV2 BVL 3MCG/0.2ML 2ND DOSE (MAROON CAP) | 1 | 6MO- 4YRS | 40.00 |
| 0173A | PFIZER | ADM SARSCV2 BVL 3MCG/0.2ML 3RD DOSE (MAROON CAP) | 1 | 6MO- 4YRS | 40.00 |

PRESCRIBED DRUGS IMMUNIZATION FEE SCHEDULE

EFFECTIVE: OCTOBER 1, 2023

| Code | Modifier | Description | Units | Age (Years) | MaxFee |
|-------------|-----------------|--|--------------|--------------------|---------------|
| 0174A | PFIZER | ADM SARSCV2 BVL 3MCG/0.2ML ADDITIONAL DOSE (MAROON CAP) | 1 | 6MO- 4YRS | 40.00 |
| 91313 | MODERNA | SARSCOV2 VAC BVL 50MCG/0.5ML (DARK BLUE CAP GRAY BORDER) | 1 | 12+ | 0.00 |
| 0134A | MODERNA | ADM SARSCV2 BVL 50MCG/.5ML BOOSTER (DARK BLUE CAP GRAY BORDER) | 1 | 12+ | 40.00 |
| 91314 | MODERNA | SARSCOV2 VAC BVL 25MCG/0.25ML (DARK BLUE CAP GRAY BORDER) | 1 | 6MO-11YRS | 0.00 |
| 0141A | MODERNA | ADM SARSCV2 BVL 25MCG/0.25ML FIRST DOSE (DARK BLUE CAP GRAY BORDER) | 1 | 6MO-11YRS | 40.00 |
| 0142A | MODERNA | ADM SARSCV2 BVL 25MCG/0.25ML 2ND DOSE (DARK BLUE CAP GRAY BORDER) | 1 | 6MO-11YRS | 40.00 |
| 0144A | MODERNA | ADM SARSCV2 BVL 25MCG/0.25ML ADDITIONAL DOSE (DARK BLUE CAP GRAY BORDER) | 1 | 6MO-11YRS | 40.00 |
| 91316 | MODERNA | SARSCOV2 VAC BVL 10MCG/0.2ML (DARK PINK CAP) | 1 | 6MO- 4YRS | 0.00 |
| 0164A | MODERNA | ADM SRSVC2 BLV 10MCG/0.2ML ADDITIONAL DOSE (DARK PINK CAP) | 1 | 6MO- 4YRS | 40.00 |
| 0041A | NOVAVAX | ADM NOVAVAX COVID-19 VACCINE, ADJUVANTED DOSE 1 | 1 | 12+ | 40.00 |
| 0042A | NOVAVAX | ADM NOVAVAX COVID-19 VACCINE, ADJUVANTED DOSE 2 | 1 | 12+ | 40.00 |
| 0044A | NOVAVAX | ADM NOVAVAX COVID-19 VACCINE, ADJUVANTED ADDITIONAL DOSE | 1 | 18+ | 40.00 |